Monthly Archives: March 2018

Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases

2018-03-08T12:03:05+00:00

Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases Lead investor Venrock joined by Celgene, Lightstone and DROIA Markus Renschler, M.D., joins as CEO, from Celgene Financing proceeds will be used to advance RAD51 inhibitor toward the clinic and expand small-molecule synthetic lethality platform for [...]

Cyteir Therapeutics Secures $29 Million Series B to Advance Novel, Molecularly Targeted Therapies for Cancer and Autoimmune Diseases 2018-03-08T12:03:05+00:00